Head and Neck Squamous Cell Cancer Clinical Trial
Official title:
An Intervention Study Comparing Intensive Nutrition Counselling With On-demand Counselling in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy
The purpose of this study is to assess the effect of a pre-planned patient-adjusted intensive nutritional counselling given by a dietitian several times during (chemo)radiotherapy vs. individualized nutritional counselling given by a dietitian once in the beginning of (chemo)radiotherapy and thereafter on-demand in patients with head and neck squamous cell cancer.
- A sample size of 102 patients was identified to achieve 30% reduction in prevalence of
malnutrition at the end of treatment (50% to 20%), with a significance value of 5% (p <
0.05), 90% power. The second calculation was for a sample size of 88 patients for 30%
reduction in prevalence of malnutrition at the end of treatment (50% to 20%) with the
significance value 5% (p<0.05), 85% power and effect size 70%. Based on these numbers,
our aim is to recruit 100 patients, with the assumption that 12% patients would be lost
to follow up.
- Randomization will be performed by the minimization procedure with the Minim Program®
(http://www-users.york.ac.uk/~mb55/guide/randsery.htm). The allocation will be done
according to the following criteria: 1) Stage I-II vs. Stage III-IV; 2) age <65 vs.
>=65 year; 3) Body Mass Index <20 vs. >=20 kg/m2 and 4) tumour location (oral
cavity-oropharynx-tonsils vs. hypopharynx-larynx vs. nasopharynx).
- Adverse events of chemoradiotherapy will be classified according to the National Cancer
Institute Common Terminology Criteria for Adverse Events-3.0 (CTCAE v3.0)
- Nutritional status will be assessed by patient-generated subjective global assessment,
nutritional risk screening-2002, upper-arm anthropometry (MAC, triceps skinfold
thickness, MAMA), Bio-impedance, hand grip strength and weight loss.
- Survival: overall survival, disease-specific survival and disease-free survival are
calculated.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03667482 -
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
|
Phase 1 | |
Completed |
NCT02083692 -
Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
|
Early Phase 1 | |
Completed |
NCT02282371 -
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
|
Phase 1 | |
Active, not recruiting |
NCT03138070 -
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
|
N/A | |
Completed |
NCT02252042 -
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
|
Phase 3 | |
Terminated |
NCT01790516 -
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
|
N/A | |
Completed |
NCT00574977 -
Safety Study of Modified Vaccinia Virus to Cancer
|
Phase 1 | |
Completed |
NCT00592371 -
Head and Neck Cancer Screening and Serum Repository
|
N/A | |
Recruiting |
NCT02485548 -
Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer
|
Phase 3 | |
Terminated |
NCT01326923 -
Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
|
Phase 2 | |
Not yet recruiting |
NCT03975270 -
Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )
|
Phase 2 | |
Terminated |
NCT04187872 -
LITT and Pembrolizumab in Recurrent Brain Metastasis
|
Phase 1 | |
Recruiting |
NCT02327468 -
Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers
|
Phase 1 | |
Active, not recruiting |
NCT01351103 -
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
|
Phase 1 | |
Terminated |
NCT00260598 -
LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer
|
Phase 2 | |
Completed |
NCT02163057 -
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04856631 -
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
|
Phase 1/Phase 2 |